Inhibitor of Interferon type I (IFN-I) is capable of inhibiting the inflammatory response in those autoimmune diseases in which this cytokine is involved, called interferonopathies, such as systemic lupus erythematosus and Aicardi-Goutières syndrome.
A new immunotherapy strategy based on the administration of ADCs or CAR-T cells derived from a monoclonal antibody specific for the pre-TCR receptor, which impairs LIC activity and tumor progression, has been developed and validated in a preclinical human T-ALL xenotransplantation model in mice.
Novel compounds based on a repurposed drug to combat gram (+) bacterial infections.
New family of molecules derived from Isoquercetin for the treatment and/or prevention of inflammatory and degenerative eye diseases.
Novel Hydrogel with optimized mechanical and structural properties to resemble artificial lymph nodes and improve primary human CAR-T cell manufacture.
Compounds useful as reversible light-regulated agonists for activation of Vitamin D receptor (VDR) using wavelengths suitable for phototherapy, that would avoid the appearance of secondary effects, with application for the treatment of diseases that involve an alteration of the VDR function.
A recombinant gluten degrading protein that may have application as an agent or food additive for the prevention of gluten-mediated conditions, as well as in the food industry for the manufacturing of gluten-free products.
New family of molecules (low-molecular weight peptides) present in olive oil with blood pressure-reducing activity for hypertensive people
Design of a novel proteolytic set of chimeras (26STACs) directed at the degradation of the ceramide transfer protein CERT-1 by the proteasome, in an E3-independent manner, for its use in the treatment of breast cancer.
Effective triple-negative breast cancer treatment based on the modulation of the phenotype of CD206+ tumor associated macrophages by means of a novel peptide-drug-conjugate (PDC) which is able to slow tumor progression and supress lung metastasis.